{"id":68772,"date":"2026-02-21T15:51:18","date_gmt":"2026-02-21T15:51:18","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68772"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"retatrutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/retatrutide\/","title":{"rendered":"Retatrutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Retatrutid?<\/h3>\n<p style=\"margin: 0;\">Retatrutid (LY3437943) je v\u00fdzkumn\u00fd peptid a prvn\u00ed <strong>trojit\u00fd agonist receptor\u016f<\/strong> c\u00edlen\u00ed na receptory GLP-1, GIP a glukagonu v jedn\u00e9 molekule. Ve studi\u00edch f\u00e1ze 2 (Jastreboff 2023, NEJM) dos\u00e1hl pr\u016fm\u011brn\u00e9ho sn\u00ed\u017een\u00ed hmotnosti o <strong>24,2 % za 48 t\u00fddn\u016f<\/strong> \u2013 vy\u0161\u0161\u00ed ne\u017e jak\u00fdkoli jin\u00fd publikovan\u00fd metabolick\u00fd peptid dosud. K dispozici v lyofilizovan\u00fdch vial\u00e1ch o s\u00edle 5 mg a\u017e 60 mg pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2381089-83-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item2<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4731,4 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Modifikovan\u00fd trojit\u00fd agonista GIP\/GLP-1\/GCGR (39 zbytk\u016f, lipidovan\u00fd; propriet\u00e1rn\u00ed Lilly LY-3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">item12<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Co je Retatrutid<\/h2>\n<p><strong>Retatrutide<\/strong> (experiment\u00e1ln\u00ed ozna\u010den\u00ed <strong>LY3437943<\/strong>) je syntetick\u00fd 39-aminokyselinov\u00fd peptid vyvinut\u00fd spole\u010dnost\u00ed Eli Lilly jako prvn\u00ed klinicky testovan\u00fd trojit\u00fd agonista receptor\u016f GLP-1, GIP a glukagonu. Zat\u00edmco d\u0159\u00edv\u011bj\u0161\u00ed inkretinov\u00e9 peptidy p\u016fsob\u00ed na jeden receptor (semaglutid \u2013 GLP-1) nebo dva (tirzepatid \u2013 GLP-1 plus GIP), retatrutid aktivuje v\u0161echny t\u0159i metabolick\u00e9 receptory sou\u010dasn\u011b. Tato odli\u0161n\u00e1 farmakologie je studov\u00e1na u obezity, diabetu 2. typu, nealkoholick\u00e9 tukov\u00e9 choroby jater (NAFLD\/MASH) a metabolick\u00e9ho syndromu spojen\u00e9ho s hypertenz\u00ed.<\/p>\n<p>Peptid m\u00e1 molekulovou hmotnost p\u0159ibli\u017en\u011b 4 731,4 Da, empirick\u00fd vzorec C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub>, a je dod\u00e1v\u00e1n jako vysoce \u010dist\u00fd lyofilizovan\u00fd pr\u00e1\u0161ek pro rekonstituci s bakteriostatickou vodou. Je <strong>ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro hum\u00e1nn\u00ed nebo veterin\u00e1rn\u00ed diagnostiku \u010di terapii. Pro podrobn\u011bj\u0161\u00ed informace o mechanismu, studi\u00edch a v\u00fdhledech viz n\u00e1\u0161 kompletn\u00ed <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-triple-agonist-weight-loss-guide\/\">Pr\u016fvodce v\u00fdzkumem Retatrutidu<\/a>.<\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 trojit\u00fd agonista GLP-1\/GIP\/glukagon<\/h2>\n<p>Profil receptor\u016f Retatrutidu je to, co jej odli\u0161uje od v\u0161ech ostatn\u00edch metabolick\u00fdch peptid\u016f, kter\u00e9 jsou aktu\u00e1ln\u011b na trhu nebo v pozdn\u00edch f\u00e1z\u00edch klinick\u00fdch studi\u00ed. Ka\u017ed\u00fd ze t\u0159\u00ed receptor\u016f p\u0159isp\u00edv\u00e1 odli\u0161nou drahou k pozorovan\u00fdm \u00fa\u010dink\u016fm na t\u011blesn\u00e9 slo\u017een\u00ed, kontrolu gluk\u00f3zy a energetickou bilanci:<\/p>\n<ul>\n<li><strong>Receptor GLP-1<\/strong> \u2014 stejn\u00fd receptor, kter\u00fd aktivuj\u00ed semaglutid (Ozempic, Wegovy) a liraglutid. Agonismus zpomaluje vyprazd\u0148ov\u00e1n\u00ed \u017ealudku, zesiluje sign\u00e1ly sytosti v hypotalamu a stimuluje gluk\u00f3zo-z\u00e1vislou sekreci inzul\u00ednu z pankreatick\u00fdch beta bun\u011bk.<\/li>\n<li><strong>Receptor GIP<\/strong> \u2014 druh\u00e1 dr\u00e1ha p\u0159idan\u00e1 tirzepatidem (Mounjaro, Zepbound). Agonismus GIP zlep\u0161uje inzulinovou senzitivitu v tukov\u00e9 tk\u00e1ni, sni\u017euje strop nevolnosti u samotn\u00e9ho GLP-1 a podporuje efektivitu tukov\u00fdch bun\u011bk v zach\u00e1zen\u00ed s lipidy.<\/li>\n<li><strong>Receptor glukagonu<\/strong> \u2014 nov\u00e1 t\u0159et\u00ed dr\u00e1ha, kter\u00e1 je unik\u00e1tn\u00ed pro retatrutid. Agonismus glukagonu zvy\u0161uje baz\u00e1ln\u00ed energetick\u00fd v\u00fddej, podporuje oxidaci lipid\u016f v j\u00e1trech a sni\u017euje jatern\u00ed tuk \u2014 \u00fa\u010dinky, kter\u00e9 dvojice GLP-1\/GIP nedok\u00e1\u017ee replikovat.<\/li>\n<\/ul>\n<p>Proto\u017ee zv\u00fd\u0161en\u00fd energetick\u00fd v\u00fddej prost\u0159ednictv\u00edm glukagonu se aditivn\u011b p\u0159id\u00e1v\u00e1 k potla\u010den\u00ed chuti k j\u00eddlu zp\u016fsoben\u00e9mu GLP-1\/GIP, retatrutid vytv\u00e1\u0159\u00ed jak v\u011bt\u0161\u00ed energetick\u00fd deficit, tak p\u0159\u00edzniv\u011bj\u0161\u00ed profil t\u011blesn\u00e9ho slo\u017een\u00ed v preklinick\u00fdch modelech ne\u017e du\u00e1ln\u00ed agonist\u00e9 peptid\u016f. Ve v\u00fdzkumn\u00fdch datech f\u00e1ze 2 tvo\u0159ila ztr\u00e1ta tukov\u00e9 hmoty v\u011bt\u0161inu celkov\u00e9ho \u00fabytku hmotnosti, s zachovanou svalovou hmotou ve vy\u0161\u0161\u00edch d\u00e1vkov\u00fdch skupin\u00e1ch.<\/p>\n<h2>Publikovan\u00e1 v\u00fdzkumn\u00e1 data<\/h2>\n<p>Hlavn\u00ed soubor dat retatrutidu poch\u00e1z\u00ed ze studie f\u00e1ze 2 o obezit\u011b publikovan\u00e9 Jastreboffem a kolegy v <em>New England Journal of Medicine<\/em> v \u010dervnu 2023 (n = 338 \u00fa\u010dastn\u00edk\u016f s obezitou, 48t\u00fddenn\u00ed l\u00e9\u010debn\u00e9 obdob\u00ed). P\u0159i nejvy\u0161\u0161\u00ed testovan\u00e9 d\u00e1vce 12 mg t\u00fddn\u011b dos\u00e1hli \u00fa\u010dastn\u00edci pr\u016fm\u011brn\u00e9ho sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti o <strong>24,2 % oproti v\u00fdchoz\u00ed hodnot\u011b<\/strong>. Srovn\u00e1vac\u00ed skupina se semaglutidem ve studii STEP-1 zaznamenala sn\u00ed\u017een\u00ed o 14,9 % za 68 t\u00fddn\u016f a skupina s tirzepatidem ve studii SURMOUNT-1 dos\u00e1hla sn\u00ed\u017een\u00ed o 22,5 % za 72 t\u00fddn\u016f \u2014 retatrutid tedy dos\u00e1hl \u010d\u00edseln\u011b v\u011bt\u0161\u00edho sn\u00ed\u017een\u00ed v krat\u0161\u00edm l\u00e9\u010debn\u00e9m obdob\u00ed. P\u0159\u00edm\u00e9 srovn\u00e1vac\u00ed studie zat\u00edm nebyly publikov\u00e1ny.<\/p>\n<p>Paraleln\u00ed program f\u00e1ze 2 pro diabetes (Rosenstock et al., <em>Lancet<\/em> 2023) prok\u00e1zal sn\u00ed\u017een\u00ed HbA1c a\u017e o 2,16 procentn\u00edch bod\u016f za 36 t\u00fddn\u016f u \u00fa\u010dastn\u00edk\u016f s diabetem 2. typu, op\u011bt p\u0159i t\u00fddenn\u00ed d\u00e1vce 12 mg. D\u00edl\u010d\u00ed studie f\u00e1ze 2 pro NAFLD zaznamenala relativn\u00ed sn\u00ed\u017een\u00ed obsahu jatern\u00edho tuku o 51,3 % po 24 t\u00fddnech p\u0159i d\u00e1vce 8 mg \u2014 dosud nejv\u011bt\u0161\u00ed sn\u00ed\u017een\u00ed jatern\u00edho tuku zaznamenan\u00e9 u jak\u00e9hokoli peptidu ze t\u0159\u00eddy inkretin\u016f.<\/p>\n<p>Spole\u010dnost Eli Lilly v sou\u010dasn\u00e9 dob\u011b prov\u00e1d\u00ed program f\u00e1ze 3 TRIUMPH, kter\u00fd zahrnuje <strong>TRIUMPH-1<\/strong> (obezita), <strong>TRIUMPH-2<\/strong> (obezita s diabetem 2. typu), <strong>TRIUMPH-3<\/strong> (obezita s kardiovaskul\u00e1rn\u00edm onemocn\u011bn\u00edm) a <strong>TRIUMPH-4<\/strong> (sp\u00e1nkov\u00e1 apnoe a obezita). V\u00fdsledky f\u00e1ze 3 by m\u011bly p\u0159isp\u011bt k budouc\u00ed registra\u010dn\u00ed \u017e\u00e1dosti.<\/p>\n<h2>V\u00fdzkumn\u00e9 aplikace<\/h2>\n<p>Retatrutid se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zam\u011b\u0159en\u00e9m na:<\/p>\n<ul>\n<li><strong>Obezitu a regulaci t\u011blesn\u00e9 hmotnosti<\/strong> \u2014 mechanistick\u00e9 studie signalizace chuti k j\u00eddlu, kinetiky vyprazd\u0148ov\u00e1n\u00ed \u017ealudku a energetick\u00e9ho v\u00fddeje u hlodavc\u016f a in-vitro model\u016f<\/li>\n<li><strong>Citlivost na inzulin a homeost\u00e1zu gluk\u00f3zy<\/strong> \u2014 \u00fa\u010dinky na sekreci inzulinu, jatern\u00ed produkci gluk\u00f3zy a perifern\u00ed vyu\u017eit\u00ed gluk\u00f3zy<\/li>\n<li><strong>Jatern\u00ed steat\u00f3za\/MASH<\/strong> \u2014 mobilizace jatern\u00edho tuku a odpov\u011b\u010f transamin\u00e1z ve v\u00fdzkumn\u00fdch modelech tukov\u00e9 jater<\/li>\n<li><strong>Farmakologie receptor\u016f<\/strong> \u2014 srovn\u00e1vac\u00ed studie vazby, selektivity a n\u00e1sledn\u00e9 signalizace u trojice receptor\u016f GLP-1\/GIP\/glukagon<\/li>\n<li><strong>Srovn\u00e1vac\u00ed v\u00fdzkum metabolick\u00fdch peptid\u016f<\/strong> \u2014 benchmarkov\u00e1n\u00ed v\u016f\u010di tirzepatidu (du\u00e1ln\u00edmu agonistovi GLP-1\/GIP) a dal\u0161\u00edm zkouman\u00fdm slou\u010denin\u00e1m z hlediska \u00fa\u010dinnosti, sn\u00e1\u0161enlivosti a v\u00fdsledk\u016f t\u011blesn\u00e9ho slo\u017een\u00ed. Viz na\u0161e <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide-tirzepatide-vs-semaglutide\/\">srovn\u00e1n\u00ed tirzepatidu se semaglutidem<\/a> pro z\u00e1kladn\u00ed linii du\u00e1ln\u00edho agonismu.<\/li>\n<li><strong>Stackov\u00e1n\u00ed peptid\u016f pro hojen\u00ed a regeneraci<\/strong> \u2014 v\u00fdzkumn\u00e9 protokoly kombinuj\u00edc\u00ed metabolick\u00e9 peptidy s reparativn\u00edmi slou\u010deninami jako je <a href=\"https:\/\/medsbase.com\/cs\/bpc-157\/\">BPC-157<\/a> v preklinick\u00fdch studi\u00edch.<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext, kam se retatrutid \u0159ad\u00ed v oblasti peptid\u016f pro redukci hmotnosti, viz n\u00e1\u0161 <a href=\"https:\/\/medsbase.com\/cs\/peptide-stacks-for-fat-loss\/\">pr\u016fvodce stacky peptid\u016f pro v\u00fdzkum \u00fabytku tuku<\/a> a celkov\u00fd <a href=\"https:\/\/medsbase.com\/cs\/glp-1-weight-loss-injections-guide\/\">pr\u016fvodce injekcemi GLP-1 pro redukci hmotnosti<\/a>. Prohl\u00e9dn\u011bte si kompletn\u00ed <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog v\u00fdzkumn\u00fdch peptid\u016f<\/a> pro p\u0159\u00edbuzn\u00e9 slou\u010deniny.<\/p>\n<h2>Dostupn\u00e9 s\u00edly a koncentrace<\/h2>\n<p>MedsBase nab\u00edz\u00ed retatrutid v n\u00e1sleduj\u00edc\u00edch lyofilizovan\u00fdch velikostech vialek. Ka\u017ed\u00e1 varianta je dod\u00e1v\u00e1na v balen\u00ed po 10 nebo 20 vialk\u00e1ch, expedov\u00e1na v chlazen\u00fdch podm\u00ednk\u00e1ch s n\u00e1vodem na rekonstituci:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typick\u00e9 pou\u017eit\u00ed<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pilotn\u00ed d\u00e1vkovac\u00ed studie, titra\u010dn\u00ed postup<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standardn\u00ed v\u00fdzkumn\u00e1 s\u00edla, nej\u010dast\u011bji objedn\u00e1van\u00e1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Soulad s d\u00e1vkami ve studi\u00edch (vysokod\u00e1vkov\u00e1 skupina f\u00e1ze 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Roz\u0161\u00ed\u0159en\u00e9 v\u00fdzkumn\u00e9 protokoly, hromadn\u00e1 p\u0159\u00edprava<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hromadn\u00fd v\u00fdzkum (m\u00e9n\u011b rekonstituc\u00ed na protokol)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00fdzkum s vysokou propustnost\u00ed, optimalizace n\u00e1klad\u016f na mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pou\u017eit\u00ed v laborato\u0159i pro velk\u00e9 \u0161ar\u017ee<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maxim\u00e1ln\u00ed mo\u017enost pro hromadn\u00e9 n\u00e1kupy, v\u00fdzkum s nejdel\u0161\u00ed dobou trv\u00e1n\u00ed<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>V\u0161echny s\u00edly jsou dod\u00e1v\u00e1ny ve stejn\u00e9 chemick\u00e9 form\u011b (lyofilizovan\u00fd pr\u00e1\u0161ek, \u010distota 99%+ HPLC). V\u011bt\u0161\u00ed mg lahvi\u010dky nab\u00edzej\u00ed ni\u017e\u0161\u00ed n\u00e1klady na mg, ale vy\u017eaduj\u00ed men\u0161\u00ed objemy rekonstituce pro zachov\u00e1n\u00ed standardn\u00edch koncentrac\u00ed U-100 st\u0159\u00edka\u010dek \u2014 viz tabulka \u0159ed\u011bn\u00ed n\u00ed\u017ee.<\/p>\n<h2>Srovn\u00e1n\u00ed \u2014 Retatrutid vs Tirzepatid vs Semaglutid<\/h2>\n<p>N\u00e1sleduj\u00edc\u00ed shrnut\u00ed vych\u00e1z\u00ed z publikovan\u00fdch klinick\u00fdch \u00fadaj\u016f. Retatrutid je st\u00e1le ve f\u00e1zi 3 v\u00fdvoje a n\u00ed\u017ee uveden\u00e1 srovn\u00e1n\u00ed poch\u00e1zej\u00ed z odd\u011blen\u00fdch studi\u00ed, nikoli z p\u0159\u00edm\u00e9ho srovn\u00e1n\u00ed.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptorov\u00e9 c\u00edle<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glukagon (trojit\u00fd agonista)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (du\u00e1ln\u00ed agonista)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (jednoduch\u00fd agonista)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Maxim\u00e1ln\u00ed publikovan\u00fd \u00fabytek hmotnosti<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">24,2 % za 48 t\u00fddn\u016f<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">22,5 % za 72 t\u00fddn\u016f<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">14,9 % za 68 t\u00fddn\u016f<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Frekvence d\u00e1vkov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">T\u00fddn\u011b<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">T\u00fddn\u011b<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">T\u00fddn\u011b<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Regula\u010dn\u00ed status<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">F\u00e1ze 3 (TRIUMPH) \u2014 v\u00fdzkumn\u00fd<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Schv\u00e1leno FDA (Mounjaro\/Zepbound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Schv\u00e1leno FDA (Ozempic\/Wegovy)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Redukce jatern\u00edho tuku<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">51,3 % ve 24. t\u00fddnu (f\u00e1ze 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~47 % v 52. t\u00fddnu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~31 % v 72. t\u00fddnu<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sn\u00ed\u017een\u00ed HbA1c (T2DM)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A\u017e -2,16 % v 36. t\u00fddnu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A\u017e -2,3 % v 40. t\u00fddnu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A\u017e -1,8 % v 40. t\u00fddnu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Pro podrobn\u011bj\u0161\u00ed srovn\u00e1n\u00ed tirzepatidu versus semaglutidu viz <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide-tirzepatide-vs-semaglutide\/\">Tirzepatid vs Semaglutid: \u00dabytek hmotnosti, d\u00e1vkov\u00e1n\u00ed &amp; cena<\/a>.<\/p>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p><strong>P\u0159ed rekonstituci:<\/strong> lyofilizovan\u00e9 lahvi\u010dky skladujte v chladni\u010dce p\u0159i teplot\u011b 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu z f\u00f3lie. Za t\u011bchto podm\u00ednek z\u016fst\u00e1v\u00e1 lyofilizovan\u00fd retatrutid stabiln\u00ed a\u017e 36 m\u011bs\u00edc\u016f. Vyvarujte se opakovan\u00e9ho kol\u00eds\u00e1n\u00ed teplot.<\/p>\n<p><strong>Postup rekonstituce:<\/strong> p\u0159idejte bakteriostatickou vodu do lahvi\u010dky s peptidem podle v\u00fd\u0161e uveden\u00e9 tabulky \u0159ed\u011bn\u00ed. Vodu vst\u0159\u00edkn\u011bte po stran\u011b lahvi\u010dky, nikoli p\u0159\u00edmo na lyofilizovanou hmotu. Jemn\u011b zakru\u017ete \u2014 ne <strong>ne<\/strong> prot\u0159ep\u00e1vejte \u2014 a nechte 5\u201310 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed. Pln\u011b rekonstituovan\u00fd roztok by m\u011bl b\u00fdt \u010dir\u00fd a bezbarv\u00fd.<\/p>\n<p><strong>Po rekonstituci:<\/strong> roztok skladujte v chladni\u010dce p\u0159i teplot\u011b 2\u20138 \u00b0C a pou\u017eijte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu. Rekonstituovan\u00fd roztok nezmrazujte \u2014 cykly zmrazen\u00ed a rozmrazen\u00ed naru\u0161uj\u00ed integritu peptidu. Zlikvidujte jakoukoli lahvi\u010dku projevuj\u00edc\u00ed z\u00e1kal, sra\u017eeniny nebo zm\u011bnu barvy.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>K \u010demu se retatrutid pou\u017e\u00edv\u00e1 ve v\u00fdzkumu?<\/h3>\n<p>Retatrutid se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zam\u011b\u0159en\u00e9m na obezitu, diabetes 2. typu, nealkoholick\u00e9 tukov\u00e9 onemocn\u011bn\u00ed jater (NAFLD\/MASH), inzulinovou senzitivitu, regulaci chuti k j\u00eddlu a srovn\u00e1vac\u00ed farmakologii metabolick\u00fdch peptid\u016f. Nen\u00ed <strong>ne<\/strong> schv\u00e1len FDA, EMA ani jin\u00fdmi regul\u00e1tory pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed a je zde prod\u00e1v\u00e1n v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<h3>\u010c\u00edm se retatrutid li\u0161\u00ed od tirzepatidu a semaglutidu?<\/h3>\n<p>Retatrutid je prvn\u00ed trojit\u00fd agonista receptor\u016f, kter\u00fd v\u00e1\u017ee receptory GLP-1, GIP a, <em>a<\/em> glukagonu v jedn\u00e9 molekule. Tirzepatid v\u00e1\u017ee receptory GLP-1 a GIP (du\u00e1ln\u00ed). Semaglutid v\u00e1\u017ee pouze receptor GLP-1 (jednoduch\u00fd). P\u0159idan\u00e1 glukagonov\u00e1 dr\u00e1ha v retatrutidu zvy\u0161uje energetick\u00fd v\u00fddej a sni\u017euje jatern\u00ed tuk zp\u016fsobem, kter\u00fd du\u00e1ln\u00ed a jednoduch\u00e9 agonisty nedok\u00e1\u017eou replikovat.<\/p>\n<h3>Jak\u00fd \u00fabytek hmotnosti byl pozorov\u00e1n u retatrutidu v klinick\u00fdch studi\u00edch?<\/h3>\n<p>F\u00e1ze 2 studie obezity publikovan\u00e9 Jastreboffem et al. v NEJM (2023) uv\u00e1d\u00ed pr\u016fm\u011brn\u00e9 sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti o 24,2 % po 48 t\u00fddnech p\u0159i nejvy\u0161\u0161\u00ed testovan\u00e9 d\u00e1vce 12 mg t\u00fddn\u011b. Pro srovn\u00e1n\u00ed, nejvy\u0161\u0161\u00ed d\u00e1vka tirzepatidu ve f\u00e1zi 3 dos\u00e1hla 22,5 % po 72 t\u00fddnech a semaglutidu 14,9 % po 68 t\u00fddnech. V\u00fdsledky f\u00e1ze 3 retatrutidu z programu TRIUMPH jsou st\u00e1le o\u010dek\u00e1v\u00e1ny.<\/p>\n<h3>Je retatrutid schv\u00e1len FDA?<\/h3>\n<p>Ne. Retatrutid je aktu\u00e1ln\u011b ve f\u00e1zi 3 klinick\u00e9ho v\u00fdvoje v r\u00e1mci programu TRIUMPH spole\u010dnosti Eli Lilly a nez\u00edskal schv\u00e1len\u00ed regula\u010dn\u00edch org\u00e1n\u016f jako FDA, EMA, MHRA ani \u017e\u00e1dn\u00e9ho jin\u00e9ho \u00fa\u0159adu. Peptid prod\u00e1van\u00fd dodavateli pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely je ur\u010den pro laboratorn\u00ed v\u00fdzkum, nikoli pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed.<\/p>\n<h3>Jak\u00e9 s\u00edly nab\u00edz\u00ed MedsBase?<\/h3>\n<p>MedsBase nab\u00edz\u00ed retatrutid v lyofilizovan\u00fdch vialk\u00e1ch o s\u00edle 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg a 60 mg. Ka\u017ed\u00e1 s\u00edla je dostupn\u00e1 v balen\u00ed po 10 nebo 20 vialk\u00e1ch. V\u0161echny vialky maj\u00ed \u010distotu 99 %+ HPLC a na vy\u017e\u00e1d\u00e1n\u00ed je k dispozici certifik\u00e1t anal\u00fdzy.<\/p>\n<h3>Jak p\u0159ipravit retatrutid k pou\u017eit\u00ed?<\/h3>\n<p>Postupujte podle v\u00fd\u0161e uveden\u00e9ho \u0159edic\u00edho sch\u00e9matu. Do 10mg vialky p\u0159idejte 2,0 ml bakteriostatick\u00e9 vody, \u010d\u00edm\u017e z\u00edsk\u00e1te koncentraci 5,0 mg\/ml. 40 d\u00edlek na U-100 inzul\u00ednov\u00e9 st\u0159\u00edka\u010dce (1 ml \/ 100 jednotek) odpov\u00edd\u00e1 2 mg. BAC vodu p\u0159id\u00e1vejte po st\u011bn\u011b vialky, jemn\u011b prom\u00edchejte (net\u0159este) a nechte 5\u201310 minut rozpustit p\u0159ed pou\u017eit\u00edm.<\/p>\n<h3>Jak skladovat retatrutid?<\/h3>\n<p>Lyofilizovan\u00e9 vialky: skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu, stabilita a\u017e 36 m\u011bs\u00edc\u016f. P\u0159ipraven\u00fd roztok: skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, pou\u017eijte do 30 dn\u016f. P\u0159ipraven\u00fd roztok nezmrazujte \u2014 mrazic\u00ed cykly peptid degraduj\u00ed.<\/p>\n<h3>Jak\u00e9 jsou typick\u00e9 v\u00fdzkumn\u00e9 d\u00e1vky retatrutidu ve studi\u00edch?<\/h3>\n<p>Ve studi\u00edch f\u00e1ze 2 zam\u011b\u0159en\u00fdch na obezitu byly testov\u00e1ny t\u00fddenn\u00ed d\u00e1vky 1 mg, 4 mg, 8 mg a 12 mg po dobu 48 t\u00fddn\u016f. \u00dabytek hmotnosti byl z\u00e1visl\u00fd na d\u00e1vce, p\u0159i\u010dem\u017e v rameni s 12 mg byl pozorov\u00e1n \u00fabytek 24,2 %. Laboratorn\u00ed v\u00fdzkumn\u00e9 protokoly obvykle kop\u00edruj\u00ed tyto d\u00e1vky, pokud je c\u00edlem napodobit publikovan\u00e9 \u00fadaje o \u00fa\u010dinnosti.<\/p>\n<h3>Zp\u016fsobuje retatrutid stejn\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky jako jin\u00e9 GLP-1 peptidy?<\/h3>\n<p>V publikovan\u00fdch studi\u00edch byly nej\u010dast\u011bj\u0161\u00edmi ne\u017e\u00e1douc\u00edmi \u00fa\u010dinky gastrointestin\u00e1ln\u00ed pot\u00ed\u017ee \u2014 nevolnost, pr\u016fjem, z\u00e1cpa \u2014 podobn\u011b jako u semaglutidu a tirzepatidu. P\u0159idan\u00e1 aktivita glukagonov\u00e9ho receptoru ve f\u00e1zi 2 nevykazovala neo\u010dek\u00e1van\u00e9 bezpe\u010dnostn\u00ed sign\u00e1ly, ale \u00fapln\u00fd profil sn\u00e1\u0161enlivosti bude zn\u00e1m a\u017e po v\u00fdsledc\u00edch f\u00e1ze 3.<\/p>\n<h3>Za jak dlouho bude retatrutid schv\u00e1len FDA?<\/h3>\n<p>Program TRIUMPH f\u00e1ze 3 spole\u010dnosti Eli Lilly za\u010dal n\u00e1bor pacient\u016f v letech 2023\u20132024 s o\u010dek\u00e1van\u00fdm dokon\u010den\u00edm prim\u00e1rn\u00edch studi\u00ed v letech 2025\u20132027 v z\u00e1vislosti na d\u00edl\u010d\u00edch studi\u00edch. P\u0159i pozitivn\u00edch v\u00fdsledc\u00edch by pod\u00e1n\u00ed \u017e\u00e1dosti FDA mohlo n\u00e1sledovat 12\u201318 m\u011bs\u00edc\u016f po dokon\u010den\u00ed prim\u00e1rn\u00edch studi\u00ed. Term\u00edny schv\u00e1len\u00ed jsou spekulativn\u00ed, dokud Lilly neozn\u00e1m\u00ed pod\u00e1n\u00ed \u017e\u00e1dosti.<\/p>\n<h3>Jak\u00fd je polo\u010das rozpadu retatrutidu?<\/h3>\n<p>Retatrutide (LY3437943) m\u00e1 dlouh\u00fd elimina\u010dn\u00ed polo\u010das p\u0159ibli\u017en\u011b 6 dn\u016f podle \u00fadaj\u016f z klinick\u00e9 studie f\u00e1ze I, co\u017e je p\u0159ipisov\u00e1no modifikaci C18 mastnou kyselinou, kter\u00e1 umo\u017e\u0148uje vazbu na albumin. Tento prodlou\u017een\u00fd polo\u010das podporuje t\u00fddenn\u00ed d\u00e1vkovac\u00ed re\u017eimy pou\u017e\u00edvan\u00e9 v klinick\u00fdch studi\u00edch.<\/p>\n<h3>Jak se Retatrutide srovn\u00e1v\u00e1 s Tirzepatidem a Semaglutidem?<\/h3>\n<p>Retatrutide je trojit\u00fd agonista (receptory GLP-1 \/ GIP \/ glukagonu), ve srovn\u00e1n\u00ed s du\u00e1ln\u00edm agonismem Tirzepatidu (GLP-1 \/ GIP) a jedin\u00fdm agonismem Semaglutidu (GLP-1). \u00dadaje z klinick\u00e9 studie f\u00e1ze II pro Retatrutide uv\u00e1d\u011bj\u00ed sn\u00ed\u017een\u00ed hmotnosti a\u017e o 24 % za 48 t\u00fddn\u016f \u2013 co\u017e p\u0159ekon\u00e1v\u00e1 v\u00fdsledky jak Tirzepatidu, tak Semaglutidu ve srovnateln\u00fdch \u010dasov\u00fdch bodech. Dodate\u010dn\u00e1 aktivita receptoru glukagonu pravd\u011bpodobn\u011b zvy\u0161uje energetick\u00fd v\u00fddej a oxidaci tuk\u016f.<\/p>\n<h3>Mohu si objednat Retatrutide pro mezin\u00e1rodn\u00ed p\u0159epravu?<\/h3>\n<p>Ano. MedsBase expeduje Retatrutide po cel\u00e9m sv\u011bt\u011b prost\u0159ednictv\u00edm na\u0161\u00ed specializovan\u00e9 s\u00edt\u011b pro p\u0159epravu peptid\u016f. Objedn\u00e1vky obsahuj\u00edc\u00ed pouze peptidy se kvalifikuj\u00ed pro na\u0161i samostatnou slu\u017ebu p\u0159epravy peptid\u016f. Z\u00e1silky jsou odes\u00edl\u00e1ny v termoregulovan\u00e9m balen\u00ed s pln\u00fdm sledov\u00e1n\u00edm.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed peptidy pro v\u00fdzkum regenerace a v\u00fdkonnosti<\/h2>\n<ul>\n<li><a href=\"\/cs\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 v\u00fdzkum regenerace \u0161lach, vaz\u016f a st\u0159ev<\/li>\n<li><a href=\"\/cs\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Fragment Thymosin Beta-4 \u2014 v\u00fdzkum regenerace m\u011bkk\u00fdch tk\u00e1n\u00ed a c\u00e9v<\/li>\n<li><a href=\"\/cs\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selektivn\u00ed agonista ghrelinu \u2014 \u010dist\u00fd pulz r\u016fstov\u00e9ho hormonu bez kortizolu\/prolaktinu<\/li>\n<li><a href=\"\/cs\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Analog GHRH s prodlou\u017een\u00fdm polo\u010dasem<\/li>\n<li><a href=\"\/cs\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 M\u011b\u010fn\u00fd peptid \u2014 v\u00fdzkum regenerace k\u016f\u017ee a pojivov\u00e9 tk\u00e1n\u011b<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Dal\u0161\u00ed \u010dten\u00ed<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Seznamte se s v\u00fdzkumem tohoto peptidu<\/strong><\/p>\n<p style=\"margin: 0;\">P\u0159e\u010dt\u011bte si n\u00e1\u0161 kompletn\u00ed pr\u016fvodce zalo\u017een\u00fd na d\u016fkazech: <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-triple-agonist-weight-loss-guide\/\"><strong>Retatrutide \u2013 mechanismus \u00fa\u010dinku, data z klinick\u00fdch studi\u00ed a perspektivy<\/strong><\/a>. Pokr\u00fdv\u00e1 mechanismus \u00fa\u010dinku, publikovan\u00e1 v\u00fdzkumn\u00e1 data, obvykl\u00e9 rozsahy v\u00fdzkumn\u00e9ho d\u00e1vkov\u00e1n\u00ed, protokoly pro rekonstituci, mo\u017enosti kombinace a pozn\u00e1mky k bezpe\u010dnosti\/kontraindikac\u00edm.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Podporuje zdrav\u00e9 hubnut\u00ed a zlep\u0161enou funkci metabolismu<br data-start=\"62\" data-end=\"65\" \/>\u2705 Pom\u00e1h\u00e1 regulovat energetickou bilanci pro lep\u0161\u00ed denn\u00ed v\u00fdkon<br data-start=\"125\" data-end=\"128\" \/>\u2705 Podporuje zv\u00fd\u0161en\u00e9 spalov\u00e1n\u00ed tuk\u016f a metabolickou \u00fa\u010dinnost<br data-start=\"184\" data-end=\"187\" \/>\u2705 Pom\u00e1h\u00e1 s kontrolou chuti k j\u00eddlu a sn\u00ed\u017een\u00edm chut\u00ed<br data-start=\"239\" data-end=\"242\" \/>\u2705 Podporuje lep\u0161\u00ed celkov\u00e9 v\u00fdsledky v \u0159\u00edzen\u00ed hmotnosti<\/p>\n<p><strong>Retatrutide<\/strong> obsahuje syntetickou peptidovou slou\u010deninu.<\/p>","protected":false},"featured_media":70975,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5445,5444,5447,5446],"class_list":{"0":"post-68772","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-ly3437943","8":"product_tag-retatrutide","9":"product_tag-triple-agonist","10":"product_tag-triple-g","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/68772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=68772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/70975"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=68772"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=68772"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=68772"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=68772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}